Abstract
BackgroundThe aim of this study was to characterize the mechanical and physio-biological properties of peptide-coated stent (PCS) compared to commercialized drug-eluting stents (DESs).MethodsWKYMVm (Trp-Lys-Tyr-Met-Val-D-Met), a stimulating peptide for homing endothelial colony-forming cell was specially synthesized and coated to bare metal stent (BMS) by dopamine-derived coordinated bond. Biological effects of PCS were investigated by endothelial cell proliferation assay and pre-clinical animal study. And mechanical properties were examined by various experiment.ResultsThe peptide was well-coated to BMS and was maintained and delivered to 21 and 7 days in vitro and in vivo, respectively. Moreover, the proliferation of endothelial cell in PCS group was increased (approximately 36.4 ± 5.77%) in PCS group at 7 day of culture compare to BMS. Although, the radial force of PCS was moderated among study group. The flexibility of PCS was (0.49 ± 0.082 N) was greatest among study group. PCS did not show the outstanding performance in recoil and foreshortening test (3.1 ± 0.22% and 2.1 ± 0.06%, respectively), which was the reasonable result under the guide line of FDA (less than 7.0%). The nominal pressure (3.0 mm in a diameter) of PCS established by compliance analysis was 9 atm. The changing of PCS diameter by expansion was similar to other DESs, which is less than 10 atm of pressure for the nominal pressure.ConclusionsThese results suggest that the PCS is not inferior to commercialized DES. In addition, since the PCS was fabricated as polymer–free process, secondary coating with polymer-based immunosuppressive drugs such as –limus derivatives may possible.
Highlights
Coronary artery stent implantation is annually used to treat more than 1 million patients with obstructive coronary artery disease
It was postulated that the re-endothelialization after stent implantation may be enhanced by stimulating homing of Endothelial colongy-forming cell (ECFC) via peptide released from coronary stent
That is the reason why, previously, we have reported that our own stent design to prepare the backbone for the development of Drug-eluting stent (DES) [21, 22]
Summary
Coronary artery stent implantation is annually used to treat more than 1 million patients with obstructive coronary artery disease. With the advent of drug-eluting stents (DESs) which are coated with anti-cancer or immunosuppressive drugs, neointima growth and revascularization (2020) 24:4. WKYMVm stimulated chemotactic migration, angiogenesis, and proliferation ability of endothelial colony-forming cells (ECFCs) [8]. The G-protein-coupled FPR-2 has been implicated in regulation of inflammation and angiogenesis [9]. Based on these reports, it was postulated that the re-endothelialization after stent implantation may be enhanced by stimulating homing of ECFCs via peptide released from coronary stent. The aim of this study was to characterize the mechanical and physio-biological properties of peptidecoated stent (PCS) compared to commercialized drug-eluting stents (DESs)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
